Fecal Incontinence Market Report 2026

The fecal incontinence market size has grown strongly in recent years. It will grow from $2.32 billion in 2025 to $2.47 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to rising geriatric population levels, increasing prevalence of gastrointestinal disorders, wider availability of disposable continence products, growing awareness of bowel health conditions, improved diagnosis of pelvic floor dysfunction.

The fecal incontinence market size is expected to see strong growth in the next few years. It will grow to $3.18 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to increasing adoption of non-invasive treatment approaches, rising demand for personalized continence care, growing home healthcare penetration, expansion of digital pelvic floor therapy tools, increasing healthcare focus on quality of life improvement. Major trends in the forecast period include increasing adoption of advanced absorbent products, rising use of electrical stimulation therapies, growing preference for home-based management solutions, expansion of minimally invasive treatment options, enhanced focus on patient comfort and discretion.

The rising prevalence of gastrointestinal disorders is expected to drive the growth of the fecal incontinence market in the coming years. Gastrointestinal (GI) disorders are conditions that impact the digestive system, including the esophagus, stomach, intestines, liver, pancreas, and gallbladder. The incidence of gastrointestinal disorders is increasing due to poor dietary habits and lifestyle changes, such as high consumption of processed foods and low fiber intake. Disorders like inflammatory bowel disease (IBD), chronic diarrhea, and irritable bowel syndrome (IBS) can lead to fecal incontinence by impairing bowel function in multiple ways. For example, in June 2023, Crohn's and Colitis Canada, a charity supporting people with Crohn's or colitis, reported that the number of individuals living with IBD is projected to rise from 322,600 in 2023 (0.8% of the population) to 470,000 by 2035 (1.1% of the population). Additionally, 11,000 new cases were expected in 2023 (one diagnosis every 48 minutes), increasing to 14,000 new cases by 2035 (one every 38 minutes). Consequently, the growing prevalence of gastrointestinal disorders is propelling the fecal incontinence market.

Major companies in the fecal incontinence market are focusing on developing innovative solutions, such as pelvic health systems, to improve patient comfort, enhance treatment outcomes, and expand market reach. Pelvic health systems encompass a range of medical technologies, services, and treatments aimed at diagnosing, managing, and improving the health of pelvic organs and structures. These systems typically address conditions affecting the pelvic floor, including incontinence, pelvic pain, and reproductive health issues. For instance, in June 2023, Axena Health Inc., a US-based medical device company, launched the Leva pelvic health system with U.S. Food and Drug Administration clearance. This system provides a convenient, non-invasive, drug-free method for strengthening pelvic floor muscles, using motion sensors and real-time feedback to guide users through effective five-minute daily exercises. By improving accessibility and efficacy through telehealth integration, the system specifically targets fecal incontinence, offering a practical solution for patients.

In January 2024, Boston Scientific Corporation, a US-based medical technology company, acquired Axonics Inc. for $3.7 billion. This acquisition is aimed at significantly enhancing Boston Scientific’s urology portfolio by integrating Axonics' innovative technologies for treating urinary and bowel dysfunction. Axonics Inc., a US-based medical device company, specializes in neuromodulation solutions for managing conditions such as overactive bladder (OAB), fecal incontinence, and urinary retention.

Major companies operating in the fecal incontinence market are 3M Company, Medtronic plc, Medline Industries LP, Essity AB, B. Braun Melsungen AG, Domtar Corporation, Coloplast Corp., HARTMANN Direct, ConvaTec Group plc, Ontex Group NV, Hollister Incorporated, Abena Group, Laborie Medical Technologies, Home Care Delivered, 180 Medical, Attends Healthcare Products Inc., Principle Business Enterprises Inc., Carewell, NorthShore Care Supply, InControl Medical, Tranquility Products, Aeroflow Urology, Reliance Medical Inc., TZMO SA, Allegro Medical.

North America was the largest region in the fecal incontinence market in 2025. The regions covered in the fecal incontinence market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fecal incontinence market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the fecal incontinence market by increasing costs of imported medical-grade polymers, electronic stimulation components, sensors, and disposable hygiene materials used in absorbent products and therapeutic devices. Healthcare providers and home care settings in North America and Europe are most affected due to reliance on imported medical supplies, while Asia-Pacific faces pricing pressure on manufacturing inputs. These tariffs are raising product costs and influencing reimbursement dynamics. However, they are also encouraging domestic manufacturing of continence products, local sourcing of materials, and innovation in cost-efficient therapeutic solutions.

The fecal incontinence market research report is one of a series of new reports that provides fecal incontinence market statistics, including fecal incontinence industry global market size, regional shares, competitors with a fecal incontinence market share, detailed fecal incontinence market segments, market trends and opportunities, and any further data you may need to thrive in the fecal incontinence industry. This fecal incontinence market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fecal incontinence is the involuntary loss of bowel control, resulting in the unintentional passage of stool or gas. Its severity can vary from occasional leakage during gas passage to a complete loss of bowel control. Contributing factors may include muscle or nerve damage, diarrhea, constipation, or underlying medical conditions such as inflammatory bowel disease or neurological disorders.

The primary product types for managing fecal incontinence include absorbent products, anal inserts, electrical stimulation devices, and other related products. Absorbent products help control incontinence by preventing leaks and providing comfort. These products are used across all age groups - pediatric, adult, and geriatric - and are applied in hospitals, clinics, home care settings, and other environments. They are distributed through multiple channels, including online stores, pharmacies, specialty retailers, and other distribution networks.

The fecal incontinence market consists of revenues earned by entities by providing services such as medical treatments, pelvic floor rehabilitation, surgical interventions, consultation, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The fecal incontinence market also includes sales of bowel management systems, anti-diarrheal drugs, laxatives, stool softeners, artificial sphincters, and nerve stimulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.